Candriam SCA’s Caribou Biosciences CRBU Stock Holding History

Candriam SCA’s Portfolio CRBU Stock Details CRBU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-625,063	Closed	-$1.03M	–	690
2024 Q2	$1.03M	Sell	625,063 -520,000	-45%	-$1.66M	0.01%	575
2024 Q1	$5.89M	Buy	1,145,063 +285,039	+33%	+$1.76M	0.04%	319
2023 Q4	$4.93M	Buy	+860,024	New	+$4.25M	0.03%	335
2023 Q2	–	Sell	-85,556	Closed	-$418K	–	759
2023 Q1	$418K	Buy	+85,556	New	+$533K	﹤0.01%	812

Other funds holding CRBU

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

EWM

Elmwood Wealth Management Berkeley, California $400M AUM 17.81% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Candriam SCA's CRBU Position: Q3 2024 in Review

Candriam SCA sold out of Caribou Biosciences (CRBU) in Q3 2024, closing a stake of 625,063 shares — an estimated $1.03M sold.

Candriam SCA first reported a position in CRBU in Q1 2023 and held it in 4 quarters. The position peaked at $5.89M in Q1 2024. 129 funds tracked by Wall St. Rank hold CRBU as of Q3 2024.

Candriam SCA reported no remaining Caribou Biosciences position as of Q3 2024 after selling out during the quarter.
Candriam SCA sold 625,063 Caribou Biosciences shares in Q3 2024, an estimated $1.03M.
Candriam SCA first reported a position in Caribou Biosciences in Q1 2023 and held it in 4 quarters.
Candriam SCA's Caribou Biosciences position peaked at $5.89M in Q1 2024.
129 funds tracked by Wall St. Rank held Caribou Biosciences as of Q3 2024.

Based on Candriam SCA's 13F filing for Q3 2024, filed 13 Nov 2024.